![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1620355
¼¼°èÀÇ COPD ¹× õ½Ä Ä¡·á¿ë µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð : ¾àÁ¦ À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Åõ¿© ¹æ¹ýº°, Áö¿ªº°, ¹üÀ§ ¹× ¿¹ÃøGlobal COPD And Asthma Drug Devices Market Size By Drug Type, By End-User, By Mode of Administration, By Geographic Scope And Forecast |
COPD ¹× õ½Ä Ä¡·á¿ë µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 382¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2030³âÀÇ ¿¹Ãø ±â°£ Áß CAGR 4.8%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 590¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°èÀÇ COPD ¹× õ½Ä Ä¡·á¿ë µð¹ÙÀ̽º ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
COPD ¹× õ½Ä Ä¡·á ±â±â ½ÃÀå ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº ´Ù¾çÇÑ ¿äÀÎÀÇ ¿µÇâÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.
È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡
½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â COPD¿Í õ½ÄÀ» Æ÷ÇÔÇÑ È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. È£Èí±â ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ È¿À²ÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä´Â Àü ¼¼°è Àα¸ÀÇ °í·ÉÈ¿Í È¯°æÀû ¿äÀÎÀÇ È®»êÀ¸·Î ÀÎÇØ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÈíÀÔ Àåºñ ±â¼ú °³¹ß :
º¸´Ù È¿°úÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î ÀåºñÀÇ °³¹ßÀº ÈíÀÔ Àåºñ ±â¼úÀÇ Áö¼ÓÀûÀÎ ±â¼ú °³¹ßÀÌ ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ÇÑ °¡Áö ¿¹¿¡ ºÒ°úÇÕ´Ï´Ù. ÈíÀÔ±â ¹× ºÐ¹«±âÀÇ ¼³°è ¹× ±â´ÉÀÇ ¹ßÀüÀº ȯÀÚÀÇ ¼øÀÀµµ¿Í °á°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
ÀÎÁöµµ ¹× ÀÎÁöµµ Çâ»ó:
¾à¹°Àü´Þ Àåºñ ½ÃÀåÀº Á¶±â ¹ß°ß, Áø´Ü ´É·Â °È, È£Èí±â Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Á¶±â Áø´ÜÀ» ÅëÇØ ½Å¼ÓÇÑ °³ÀÔ°ú Ä¡·á°¡ °¡´ÉÇϹǷΠȿÀ²ÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ÇʼöÀûÀÔ´Ï´Ù.
»ý¹°ÇÐÀû Á¦Á¦¿Í °³ÀθÂÃãÇü ÀÇ·á:
È£Èí±â Áúȯ °ü¸®¿¡ »ý¹°ÇÐÀû Ä¡·á¿Í ¸ÂÃãÇü ÀÇ·á°¡ µµÀÔµÇ¸é¼ Æ¯¼ö ¾à¹°Àü´Þ ±â±â°¡ °³¹ßµÇ¾ú°í, COPD ¹× õ½Ä Ä¡·á ±â±â ½ÃÀåÀº »ý¹°ÇÐÀû Á¦Á¦ ¹× ƯÁ¤ ȯÀÚ ¸ÂÃãÇü Ä¡·á·Î ÀÎÇØ ±â¼ú Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ȯÀÚ Áß½ÉÀû Á¢±Ù¹ý:
»ç¿ëÇϱ⠽±°í ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â Àåºñ µî ȯÀÚ Áß½ÉÀÇ ÇコÄɾ ÁßÁ¡À» µÎ¸é¼ »ç¿ëÇϱ⠽¬¿î ¾à¹°Àü´Þ ½Ã½ºÅÛ °³¹ßÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü·«Àº ȯÀÚÀÇ ÆíÀǼº°ú ¼øÀÀµµ¸¦ Çâ»ó½ÃÄÑ ½ÃÀå È®´ë¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
Á¤ºÎ Á¤Ã¥ ¹× ³ë·Â :
COPD ¹× õ½Ä Ä¡·á ±â±â ½ÃÀåÀº È£Èí±â °Ç°À» °³¼±Çϱâ À§ÇÑ Á¤ºÎ Á¤Ã¥ ¹× ±¸»ó, È£Èí±â ÀÇ·á ºÐ¾ßÀÇ ¿¬±¸ ¹× °³¹ß ÀÚ±Ý Áö¿øÀ¸·Î ÀÎÇØ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.
ÀÇ·áºñ ÁöÃâ Áõ°¡ :
ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ƯÈ÷ È£Èí±â ÁúȯÀÌ ¸¹Àº Áö¿ª¿¡¼´Â ¾à¹°Àü´Þ ±â¼úÀÇ °³¼±ÀÌ ´õ¿í Àý½ÇÇÏ°Ô ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. À̴ ƯÈ÷ °³¹ßµµ»ó±¹ÀÇ °æ¿ì, ÇコÄɾî ÀÎÇÁ¶ó°¡ ±¸ÃàµÇ°í ÀÖ´Â °³¹ßµµ»ó±¹¿¡¼´Â ´õ¿í Áß¿äÇÕ´Ï´Ù.
°í·ÉÀÚ Àα¸ Áõ°¡:
¼¼°è Àα¸°¡ °í·Éȵʿ¡ µû¶ó È£Èí±â ÁúȯÀÌ ´õ¿í º¸ÆíÈµÇ¸é¼ È¿À²ÀûÀÎ ¾à¹°Àü´Þ ¹æ¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. õ½Ä ¹× COPD ¾à¹°Àü´Þ Àåºñ ½ÃÀåÀº ÇâÈÄ ÀÌ·¯ÇÑ Àα¸ Ãß¼¼¿¡ ÀÇÇØ ÁÖµµµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
COPD ¹× õ½Ä Ä¡·á ¾à¹° Àåºñ ¼¼°è ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
COPD ¹× õ½Ä Ä¡·áÁ¦ µð¹ÙÀ̽º ½ÃÀå¿¡´Â ¸î °¡Áö ¿äÀÎÀÌ ¾ïÁ¦¿äÀÎ ¶Ç´Â °úÁ¦·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ´ÙÀ½°ú °°Àº °ÍÀÌ Æ÷ÇԵ˴ϴÙ.
³ôÀº Ä¡·áºñ :
³ôÀº Ä¡·áºñ: ÀÇ·á Á¢±Ù¼ºÀÌ ¶³¾îÁö°Å³ª ȯÀÚ°¡ Ä¡·áºñÀÇ ´ëºÎºÐÀ» ÀÚºñ·Î ºÎ´ãÇØ¾ß ÇÏ´Â Áö¿ª¿¡¼´Â ÈíÀÔ±â, ºÐ¹«±â µî COPD ¹× õ½Ä Ä¡·á ÀåºñÀÇ ºñ¿ëÀÌ È¯ÀÚ¿¡°Ô Å« °æÁ¦Àû ºÎ´ãÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
ÀÎÁöµµ ¹× Áø´ÜÀ² ÀúÁ¶:
õ½Ä ¹× COPD Áõ»ó¿¡ ´ëÇÑ °ú¼Ò Áø´Ü°ú Áö½Ä ºÎÁ·À¸·Î ÀÎÇØ Åõ¾à Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚµéÀÌ ½Å¼ÓÇÑ ÀÇ·á Á¶Ä¡¸¦ ¿ä±¸ÇÏÁö ¾ÊÀ» ¼ö ÀÖÀ¸¸ç, ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
ÈíÀÔ ±â¼úÀÇ ³À̵µ :
ȯÀÚ´Â ¿Ã¹Ù¸¥ ÈíÀÔ ±â¼ú¿¡ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖÁö¸¸, È¿À²ÀûÀÎ Ä¡·á¸¦ À§Çؼ´Â ÈíÀÔ±âÀÇ ¿Ã¹Ù¸¥ »ç¿ëÀÌ ÇʼöÀûÀÔ´Ï´Ù. ±×·¯³ª ÈíÀԱ⸦ ¿Ã¹Ù¸£°Ô »ç¿ëÇÏ´Â °ÍÀº È¿À²ÀûÀÎ Ä¡·á¸¦ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù.
¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç :
±ÔÁ¦ ±âÁØÀ» ÃæÁ·ÇÏ°í »õ·Î¿î Åõ¾à ÀåºñÀÇ ½ÂÀÎÀ» ¹ÞÀ¸·Á¸é ¿À·£ ½Ã°£°ú ¸¹Àº ÀÚ¿øÀÌ ÇÊ¿äÇϸç, ÀÌ´Â ½ÅÁ¦Ç° Ãâ½Ã°¡ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù.
Á¦³×¸¯ °æÀï»ç :
ÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÇ¸é Á¦³×¸¯ ÀǾàǰÀÇ °æÀïÀÌ Ä¡¿ÇØÁ® ¿À¸®Áö³Î ÀǾàǰ Á¦Á¶¾÷ü ½ÃÀå Á¡À¯À²°ú À繫Àû ¼º°ø¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
ºÎÀÛ¿ë ¹× ¾ÈÀü ¹®Á¦ :
õ½Ä ¹× COPD Ä¡·á¿¡ »ç¿ëµÇ´Â ¾à¹°¿¡ µû¶ó ºÎÀÛ¿ë°ú ¾ÈÀü¼º ¹®Á¦°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ȯÀÚ¿Í ÀÇ·á Àü¹®°¡°¡ ²¨¸®°Ô µÇ°í, ƯÁ¤ Åõ¾à ±â±âÀÇ º¸±ÞÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
´ë¾È Ä¡·á¹ý:
Áֻ糪 °æ±¸¿ë ¾à¹°°ú °°Àº ´ëü Ä¡·á ¿É¼ÇÀÌ ÀÖÀ¸¹Ç·Î ÈíÀÔ ±â¹Ý ¾à¹° Àåºñ ½ÃÀå Á¡À¯À²Àº ¾î·Á¿ò¿¡ Á÷¸éÇÒ ¼ö ÀÖ½À´Ï´Ù.
°Ç°°ü¸® ¼ºñ½º Á¢±Ù¼º Á¦ÇÑ:
ÀϺΠÁö¿ª°ú Àα¸ Áý´ÜÀº ÀÇ·á Àü¹®°¡¿Í ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖÀ¸¸ç, Áø´Ü°ú Ä¡·á°¡ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ÀϹÝÀûÀ¸·Î COPD ¹× õ½Ä Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
±â¼úÀû À庮 :
ƯÈ÷ °í·É ȯÀÚÀÇ °æ¿ì, º¹À⼺, ºñ¿ë, »ç¿ëÀÚ ¼ö¿ë¼º¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ÷´Ü ±â¼úÀ» Åõ¾à ±â±â¿¡ ÅëÇÕÇÏ´Â °ÍÀÌ ¾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù.
ȯ°æ¿¡ ¹ÌÄ¡´Â ¿µÇâ :
ÀϺΠÈíÀԱ⿡´Â ȯ°æ ¹®Á¦¸¦ À¯¹ßÇÏ´Â ÃßÁøÁ¦ ¹× ±âŸ ¼ººÐÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ȯ°æ À¯Áö¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¹ý±Ô°¡ °ÈµÊ¿¡ µû¶ó ¾à¼öó¸® ±â±âÀÇ ¼±Åÿ¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
COPD And Asthma Drug Devices Market size was valued at USD 38.2 Billion in 2023 and is projected to reach USD 59.04 Billion by 2030, growing at a CAGR of 4.8% during the forecast period 2024-2030.
Global COPD And Asthma Drug Devices Market Drivers
The market drivers for the COPD And Asthma Drug Devices Market can be influenced by various factors. These may include:
Growing Prevalence of Respiratory Diseases:
One major factor driving the market is the increased prevalence of respiratory conditions, including COPD and asthma. The need for efficient medicine delivery systems to treat respiratory disorders is growing as the world's population ages and environmental factors become more prevalent.
Technological Developments in Inhalation Devices:
The creation of more effective and user-friendly devices is only one example of how ongoing technological developments in inhalation device technology can propel market expansion. Better patient compliance and results are a result of the inhaler and nebulizer design and function advancements.
Increasing Recognition and Recognition Rates:
The market for medication delivery devices is expanding due to factors such as early detection, enhanced diagnostic capabilities, and rising awareness of respiratory disorders. As prompt intervention and care are made possible by early diagnosis, efficient drug administration systems are imperative.
Biologics and Personalized Medicine:
Specialized drug delivery devices have been developed as a result of the introduction of biological therapies and personalized medicine in the management of respiratory disorders. The market for COPD and asthma medication devices may see innovation spurred by biologics and customized treatments for specific patients.
Patient-Centric Approach:
The development of user-friendly medication delivery systems is being driven by a focus on patient-centric healthcare, which includes devices that are simple to use and improve patient adherence. This strategy improves patient comfort and compliance, which has a favorable effect on market expansion.
Government Policies and Initiatives:
The market for asthma and COPD medication devices can be positively impacted by government policies and initiatives that improve respiratory health as well as by funding research and development in the field of respiratory medicine.
Growing Healthcare Expenditure:
Growing healthcare spending makes improved medication delivery technologies more accessible, particularly in areas where respiratory disorders are more common. This is especially crucial in developing nations where the infrastructure supporting healthcare is growing.
Growing Senior Population:
As the world's population ages, respiratory ailments become more common, which increases the need for efficient medicine delivery methods. The market for medication devices for asthma and COPD is anticipated to be driven by this demographic trend going forward.
Global COPD And Asthma Drug Devices Market Restraints
Several factors can act as restraints or challenges for the COPD And Asthma Drug Devices Market. These may include:
High Treatment Costs:
In areas with poor access to healthcare or where patients may be required to pay a large percentage of their own treatment costs, the cost of COPD and asthma medication devices, such as inhalers and nebulizers, can be a major financial burden for patients.
Low Awareness and Diagnosis Rates:
The demand for medication devices may be hampered by underdiagnosis and a lack of knowledge about the signs of asthma and COPD. Patients might not seek prompt medical attention, which could hinder market expansion.
Difficulties with Inhaler Technique:
Although patients may experience difficulties with the correct inhalation technique, proper use of inhalers is essential for efficient treatment. This may lead to less effective drug distribution and decreased potency.
Tight Regulatory Requirements:
It can take a long time and a lot of resources to meet regulatory standards and get approvals for new medication devices, which can delay the release of new goods onto the market.
Generic Competition:
As patents for prescription drugs expire, generic copies may become more competitive, which could have an impact on the market share and financial success of original drug device manufacturers.
Side Effects and Safety Issues:
There may be side effects or safety issues with some drugs used to treat asthma and COPD. Patients' and healthcare professionals' reluctance may result from this, which may hinder the uptake of specific medication devices.
Alternative Treatment Modalities:
The market share of inhalation-based drug devices may face difficulties due to the availability of alternative treatment choices such as injections or oral drugs.
Restricted Access to Healthcare Services:
In some areas or among some populations, there may be a delay in diagnosis and treatment due to limited access to healthcare experts and facilities. This could have an impact on the demand for COPD and asthma medication devices generally.
Technological Barriers:
Concerns regarding complexity, expense, and user acceptability, particularly among older patients, may make it difficult to integrate cutting-edge technologies into medication devices.
Impact on the Environment:
Certain inhalers contain propellants or other ingredients that raise environmental issues. The market's selection of medication devices may be impacted by growing environmental sustainability awareness and legislation.
The Global COPD And Asthma Drug Devices Market is Segmented on the basis of Drug Type, End-User, Mode of Administration, and Geography.